Dianthus Therapeutics (DNTH) Tops Q2 EPS by 77c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts DNTH Hot Sheet
Join SI Premium – FREE
Dianthus Therapeutics (NASDAQ: DNTH) reported Q2 EPS of ($0.09), $0.77 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $760 thousand versus the consensus estimate of $297.42 thousand.
For earnings history and earnings-related data on Dianthus Therapeutics (DNTH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Unitil Corp. (UTL) Tops Q3 EPS by 68c
- Black Stone Minerals (BSM) Misses Q3 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
